Pfizer, Arvinas post mixed breast cancer survival results in first phase 3 test for a PROTAC degrader
Pfizer and Arvinas’ estrogen receptor degrader has failed a key part of its first phase 3 test, although the companies have pointed to success in a sub-population to suggest the therapy still has a path to regulators.
Pfizer and Arvinas’ estrogen receptor degrader has failed a key part of its first phase 3 test, although the companies have pointed to success in a sub-population to suggest the therapy still has a path to regulators.
